{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
icosapent ethyl
to a specific field?
Status:
Investigational
Source:
NCT00112554: Phase 3 Interventional Completed Leukemia
(2005)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
LAROMUSTINE is a sulfonylhydrazine alkylating agent. It is metabolized to yield a chloroethylating compound (VNP-4090-CE) and a carbamoylating compound (methyl isocyanate). The former is primarily responsible for the antineoplastic effect of LAROMUSTINE. It alkylates the O6 position of guanine, resulting in DNA crosslinking, strand breaks, chromosomal aberrations, and disruption of DNA synthesis. The carbamoylating species contribute to antitumor activity by inhibiting O6-alkylguanine transferase, an enzyme involved with DNA repair. It was studied in the treatment of several types of cancer, however, its development was discontinued.
Status:
Investigational
Source:
NCT04467905: Phase 2 Interventional Completed Atrial Fibrillation
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Etripamil is a non-dihydropyridine, L-type calcium channel blocker. Currently, etripamil is in Phase 3 development for the treatment of paroxysmal supraventricular tachycardia. Milestone Pharmaceuticals is also developing etripamil to provide rapid heartbeat control for patients living with atrial fibrillation and acute symptom relief for patients with angina.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Nicametate is a vasodilator, which enhances blood flow and oxygen to the brain, aids stroke recovery. It also can use for treating intermittent claudication in certain patients.
Status:
Investigational
Source:
NCT02575638: Phase 1 Interventional Unknown status Malignant Lymphoma of Extranodal and/or Solid Organ Site
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Camptothecin-20(S)-O-propionate (CZ48) is a prodrug of camptothecin, an alkaloid isolated from the Chinese tree Camptotheca acuminata, with potential antineoplastic activity. Upon entry into cells, camptothecin-20(S)-O-propionate is hydrolyzed by esterases into the active form camptothecin. Camptothecin selectively stabilizes topoisomerase I-DNA covalent complexes, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery. CZ48 is being investigated in clinical trials for the treatment of advanced solid tumors and lymphomas.
Status:
Investigational
Source:
NCT04052516: Phase 2 Interventional Completed Non Alcoholic Steatohepatitis (NASH)
(2019)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Icosabutate (also known as PRC-4016 or NST-4016), a cholesterol ester transfer protein inhibitor was developed by NorthSea Therapeutics for the treatment of combined dyslipidemias and hypertriglyceridemia. Icosabutate successfully completed phase II clinical trial for hypertriglyceridemic subjects, where was studied the drug efficacy and safety. In April 2018 NorthSea Therapeutics announced that its lead product, icosabutate would be further developed as an effective and safe therapeutic approach to treating both non-alcoholic steatohepatitis and its associated comorbidities.
Status:
Investigational
Source:
NCT02537938: Phase 1 Interventional Completed Alzheimer's Disease
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT03152370: Phase 1 Interventional Completed Neoadjuvant Therapy in Rectal Cancer
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Status:
Class (Stereo):
CHEMICAL (ACHIRAL)
Monophosphothiamine is thiamine derivative used for the treatment of neuritis, polyneuritis, asthenic conditions (weakness), as an additional remedy for chronic blood circulation insufficiency, chronic gastritis accompanied by motor and secretory disorders functions of the stomach. Monophosphothiamine underwent metabolic phosphorylation to active metabolite thiamine pyrophosphate, that acts as a coenzyme in the different metabolic process.
Status:
Investigational
Source:
NCT01424384: Phase 1 Interventional Completed Depressive Disorder and Anxiety Disorders
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
GlaxoSmithKline was developing GSK-424887as a dual antagonist of the human neurokinin receptor 1 and inhibitor of the serotonin transporter. GSK 424887 participated in phase I clinical trials for the treatment of depressive disorder and anxiety disorder. However, further development of GSK 424887 apparently was discontinued.
Status:
Investigational
Source:
NCT04434937: Phase 2 Interventional Completed Lymphoma
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
